| 1 | Recessive FANCM cancer syndrome with high cancer risks, chemotherapy toxicity, chromosome fragility, and gonadal failure | 3.4 | 1 | Citations (PDF) |
| 2 | Understanding the genetic complexity of puberty timing across the allele frequency spectrum | 14.1 | 56 | Citations (PDF) |
| 3 | Rare Germline Variants in DNA Repair Genes Detected in BRCA-Negative Finnish Patients with Early-Onset Breast Cancer | 2.7 | 3 | Citations (PDF) |
| 4 | FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women | 2.1 | 12 | Citations (PDF) |
| 5 | Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2 | 4.2 | 21 | Citations (PDF) |
| 6 | PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants | 4.7 | 7 | Citations (PDF) |
| 7 | Association of the
CHEK2
c.
1100delC
variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer‐specific survival | 2.0 | 10 | Citations (PDF) |
| 8 | ENIGMA
CHEK2
gether Project: A Comprehensive Study Identifies Functionally Impaired
CHEK2
Germline Missense Variants Associated with Increased Breast Cancer Risk | 4.5 | 27 | Citations (PDF) |
| 9 | NTHL1 is a recessive cancer susceptibility gene | 2.7 | 10 | Citations (PDF) |
| 10 | Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores | 3.4 | 44 | Citations (PDF) |
| 11 | Rare germline copy number variants (CNVs) and breast cancer risk | 3.1 | 14 | Citations (PDF) |
| 12 | Polygenic risk modeling for prediction of epithelial ovarian cancer risk | 2.1 | 64 | Citations (PDF) |
| 13 | Common variants in breast cancer risk loci predispose to distinct tumor subtypes | 3.4 | 30 | Citations (PDF) |
| 14 | Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes | 11.0 | 127 | Citations (PDF) |
| 15 | Breast cancer risks associated with missense variants in breast cancer susceptibility genes | 5.9 | 56 | Citations (PDF) |
| 16 | Incorporating progesterone receptor expression into the PREDICT breast prognostic model | 3.5 | 20 | Citations (PDF) |
| 17 | Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers | 3.1 | 15 | Citations (PDF) |
| 18 | Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases | 2.1 | 7 | Citations (PDF) |
| 19 | Pathogenic Variant Spectrum in Breast Cancer Risk Genes in Finnish Patients | 2.7 | 5 | Citations (PDF) |
| 20 | Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers | 0.6 | 24 | Citations (PDF) |
| 21 | Common Susceptibility Loci for Male Breast Cancer | 3.4 | 23 | Citations (PDF) |
| 22 | CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers | 4.2 | 9 | Citations (PDF) |
| 23 | A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers | 11.0 | 40 | Citations (PDF) |
| 24 | Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women | 19.4 | 1,066 | Citations (PDF) |
| 25 | Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies? | 2.7 | 8 | Citations (PDF) |
| 26 | High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome | 2.7 | 6 | Citations (PDF) |
| 27 | The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant | 3.4 | 34 | Citations (PDF) |
| 28 | Expression of markers of stem cell characteristics, epithelial-mesenchymal transition, basal-like phenotype, proliferation, and androgen receptor in metaplastic breast cancer and their prognostic impact | 1.4 | 12 | Citations (PDF) |
| 29 | Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element | 4.5 | 7 | Citations (PDF) |
| 30 | A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients | 2.7 | 6 | Citations (PDF) |
| 31 | Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment | 3.4 | 23 | Citations (PDF) |
| 32 | Mendelian randomisation study of smoking exposure in relation to breast cancer risk | 4.2 | 22 | Citations (PDF) |
| 33 | Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis | 2.7 | 4 | Citations (PDF) |
| 34 | Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness | 4.2 | 52 | Citations (PDF) |
| 35 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes | 14.1 | 171 | Citations (PDF) |
| 36 | Cancer Risks Associated With GermlinePALB2Pathogenic Variants: An International Study of 524 Families | 12.3 | 429 | Citations (PDF) |
| 37 | Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants | 3.4 | 124 | Citations (PDF) |
| 38 | Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk | 4.5 | 64 | Citations (PDF) |
| 39 | Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer | 4.7 | 8 | Citations (PDF) |
| 40 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses | 14.1 | 485 | Citations (PDF) |
| 41 | Constitutional mosaicism for a BRCA2 mutation as a cause of early-onset breast cancer | 1.1 | 12 | Citations (PDF) |
| 42 | Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk | 2.7 | 6 | Citations (PDF) |
| 43 | SNPs in lncRNA Regions and Breast Cancer Risk | 1.6 | 18 | Citations (PDF) |
| 44 | Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants | 11.0 | 64 | Citations (PDF) |
| 45 | Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D | 3.4 | 160 | Citations (PDF) |
| 46 | Transcriptome‐wide association study of breast cancer risk by estrogen‐receptor status | 2.5 | 44 | Citations (PDF) |
| 47 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis | 11.0 | 37 | Citations (PDF) |
| 48 | The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases | 2.7 | 11 | Citations (PDF) |
| 49 | Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts | 1.8 | 21 | Citations (PDF) |
| 50 | Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk | 4.2 | 59 | Citations (PDF) |
| 51 | Reply—Letter to the editor | 0.9 | 0 | Citations (PDF) |
| 52 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer | 4.7 | 45 | Citations (PDF) |
| 53 | BRCA1 mislocalization leads to aberrant DNA damage response in heterozygous ABRAXAS1 mutation carrier cells | 2.1 | 4 | Citations (PDF) |
| 54 | Two truncating variants in FANCC and breast cancer risk | 2.7 | 7 | Citations (PDF) |
| 55 | Shared heritability and functional enrichment across six solid cancers | 11.0 | 110 | Citations (PDF) |
| 56 | Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers | 4.2 | 22 | Citations (PDF) |
| 57 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer | 11.0 | 120 | Citations (PDF) |
| 58 | Recurrent moderate‐risk mutations in Finnish breast and ovarian cancer patients | 2.8 | 26 | Citations (PDF) |
| 59 | Metaplastic carcinoma of the breast: Prognosis and response to systemic treatment in metastatic disease | 0.9 | 50 | Citations (PDF) |
| 60 | Genome-wide association study of germline variants and breast cancer-specific mortality | 4.2 | 62 | Citations (PDF) |
| 61 | Prediction and clinical utility of a contralateral breast cancer risk model | 3.4 | 32 | Citations (PDF) |
| 62 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes | 4.5 | 1,063 | Citations (PDF) |
| 63 | Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study | 3.4 | 39 | Citations (PDF) |
| 64 | The BRCA2
c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity | 1.0 | 20 | Citations (PDF) |
| 65 | Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study | 4.2 | 19 | Citations (PDF) |
| 66 | E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium | 2.7 | 62 | Citations (PDF) |
| 67 | Gene‐panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication | 1.5 | 12 | Citations (PDF) |
| 68 | Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing | 3.4 | 291 | Citations (PDF) |
| 69 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk | 4.2 | 66 | Citations (PDF) |
| 70 | Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility | 1.5 | 11 | Citations (PDF) |
| 71 | rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology | 3.2 | 3 | Citations (PDF) |
| 72 | A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer | 14.1 | 232 | Citations (PDF) |
| 73 | Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci | 4.2 | 26 | Citations (PDF) |
| 74 | BRCA2
Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer | 4.2 | 90 | Citations (PDF) |
| 75 | Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk | 14.1 | 552 | Citations (PDF) |
| 76 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer | 14.1 | 512 | Citations (PDF) |
| 77 | Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility | 2.7 | 26 | Citations (PDF) |
| 78 | Association analysis identifies 65 new breast cancer risk loci | 31.3 | 1,447 | Citations (PDF) |
| 79 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer | 14.1 | 412 | Citations (PDF) |
| 80 | FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population | 1.8 | 33 | Citations (PDF) |
| 81 | Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women | 11.0 | 26 | Citations (PDF) |
| 82 | Body mass index and breast cancer survival: a Mendelian randomization analysis | 2.8 | 59 | Citations (PDF) |
| 83 | CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population | 2.1 | 36 | Citations (PDF) |
| 84 | Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study | 3.4 | 47 | Citations (PDF) |
| 85 | Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy | 1.1 | 8 | Citations (PDF) |
| 86 | Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent | 4.2 | 141 | Citations (PDF) |
| 87 | Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers | 1.5 | 12 | Citations (PDF) |
| 88 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus | 1.5 | 12 | Citations (PDF) |
| 89 | Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study | 2.8 | 83 | Citations (PDF) |
| 90 | Fine‐scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer | 2.8 | 54 | Citations (PDF) |
| 91 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS | 2.2 | 210 | Citations (PDF) |
| 92 | Patient survival and tumor characteristics associated with CHEK2:p.I157T – findings from the Breast Cancer Association Consortium | 3.4 | 51 | Citations (PDF) |
| 93 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus | 3.4 | 38 | Citations (PDF) |
| 94 | Assessing the genetic architecture of epithelial ovarian cancer histological subtypes | 1.9 | 28 | Citations (PDF) |
| 95 | Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes | 1.8 | 20 | Citations (PDF) |
| 96 | Genetic predisposition to ductal carcinoma in situ of the breast | 3.4 | 54 | Citations (PDF) |
| 97 | Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry | 1.2 | 24 | Citations (PDF) |
| 98 | Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations | 4.2 | 117 | Citations (PDF) |
| 99 | Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2 | 3.4 | 100 | Citations (PDF) |
| 100 | Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families | 1.8 | 25 | Citations (PDF) |
| 101 | Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study | 2.8 | 129 | Citations (PDF) |
| 102 | Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms | 1.6 | 42 | Citations (PDF) |
| 103 | An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression | 2.1 | 34 | Citations (PDF) |
| 104 | FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome | 2.8 | 15 | Citations (PDF) |
| 105 | rs2735383, located at a microRNA binding site in the 3’UTR of NBS1, is not associated with breast cancer risk | 2.7 | 2 | Citations (PDF) |
| 106 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types | 6.8 | 194 | Citations (PDF) |
| 107 | Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women | 3.4 | 69 | Citations (PDF) |
| 108 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer | 11.0 | 103 | Citations (PDF) |
| 109 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus | 11.0 | 92 | Citations (PDF) |
| 110 | Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs) | 2.7 | 21 | Citations (PDF) |
| 111 | No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing | 2.2 | 102 | Citations (PDF) |
| 112 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170 | 14.1 | 152 | Citations (PDF) |
| 113 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers | 3.4 | 82 | Citations (PDF) |
| 114 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer | 2.3 | 20 | Citations (PDF) |
| 115 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3 | 1.8 | 20 | Citations (PDF) |
| 116 | RAD51B in Familial Breast Cancer | 1.5 | 29 | Citations (PDF) |
| 117 | Epithelial‐Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk | 2.5 | 23 | Citations (PDF) |
| 118 | A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients | 2.1 | 11 | Citations (PDF) |
| 119 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers | 3.4 | 28 | Citations (PDF) |
| 120 | Common germline polymorphisms associated with breast cancer-specific survival | 3.4 | 29 | Citations (PDF) |
| 121 | Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers | 1.5 | 40 | Citations (PDF) |
| 122 | Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk | 1.5 | 47 | Citations (PDF) |
| 123 | Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants | 3.4 | 490 | Citations (PDF) |
| 124 | Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy | 4.5 | 13 | Citations (PDF) |
| 125 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2 | 2.1 | 41 | Citations (PDF) |
| 126 | Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1 | 4.5 | 84 | Citations (PDF) |
| 127 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer | 14.1 | 247 | Citations (PDF) |
| 128 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer | 14.1 | 588 | Citations (PDF) |
| 129 | Network-Based Integration of GWAS and Gene Expression Identifies a
HOX
-Centric Network Associated with Serous Ovarian Cancer Risk | 0.6 | 33 | Citations (PDF) |
| 130 | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression | 4.5 | 40 | Citations (PDF) |
| 131 | Identification of Novel Genetic Markers of Breast Cancer Survival | 3.4 | 65 | Citations (PDF) |
| 132 | RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families | 1.4 | 25 | Citations (PDF) |
| 133 | Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study | 2.3 | 18 | Citations (PDF) |
| 134 | Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer | 15.8 | 494 | Citations (PDF) |
| 135 | Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer | 11.0 | 70 | Citations (PDF) |
| 136 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair | 14.1 | 432 | Citations (PDF) |
| 137 | Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer | 2.2 | 28 | Citations (PDF) |
| 138 | Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis | 4.4 | 59 | Citations (PDF) |
| 139 | Shared genetics underlying epidemiological association between endometriosis and ovarian cancer | 2.1 | 79 | Citations (PDF) |
| 140 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization | 3.4 | 117 | Citations (PDF) |
| 141 | Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk | 0.6 | 26 | Citations (PDF) |
| 142 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk | 2.1 | 40 | Citations (PDF) |
| 143 | Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers | 4.2 | 10 | Citations (PDF) |
| 144 | Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium | 1.9 | 10 | Citations (PDF) |
| 145 | Screening of HELQ in breast and ovarian cancer families | 1.1 | 10 | Citations (PDF) |
| 146 | Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC) | 0.0 | 30 | Citations (PDF) |
| 147 | A Genome Wide Meta-Analysis Study for Identification of Common Variation Associated with Breast Cancer Prognosis | 1.5 | 43 | Citations (PDF) |
| 148 | MicroRNA Related Polymorphisms and Breast Cancer Risk | 1.5 | 52 | Citations (PDF) |
| 149 | Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast | 2.2 | 46 | Citations (PDF) |
| 150 | DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers | 2.2 | 55 | Citations (PDF) |
| 151 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy | 11.0 | 16 | Citations (PDF) |
| 152 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium | 2.1 | 58 | Citations (PDF) |
| 153 | Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia | 3.4 | 113 | Citations (PDF) |
| 154 | Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers | 3.4 | 63 | Citations (PDF) |
| 155 | Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer | 5.3 | 187 | Citations (PDF) |
| 156 | Alcohol Consumption and Survival after a Breast Cancer Diagnosis: A Literature-Based Meta-analysis and Collaborative Analysis of Data for 29,239 Cases | 0.6 | 48 | Citations (PDF) |
| 157 | Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche | 31.3 | 631 | Citations (PDF) |
| 158 | Breast-Cancer Risk in Families with Mutations in
PALB2 | 19.4 | 845 | Citations (PDF) |
| 159 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation | 11.0 | 112 | Citations (PDF) |
| 160 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study | 3.4 | 14 | Citations (PDF) |
| 161 | INPP4B and RAD50 have an interactive effect on survival after breast cancer | 1.8 | 8 | Citations (PDF) |
| 162 | GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer | 14.1 | 351 | Citations (PDF) |
| 163 | Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1 | 4.5 | 107 | Citations (PDF) |
| 164 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer | 14.1 | 524 | Citations (PDF) |
| 165 | Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers | 4.5 | 210 | Citations (PDF) |
| 166 | Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome | 2.8 | 10 | Citations (PDF) |
| 167 | Genome-wide association studies identify four ER negative–specific breast cancer risk loci | 14.1 | 403 | Citations (PDF) |
| 168 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk | 14.1 | 1,034 | Citations (PDF) |
| 169 | Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment | 1.8 | 37 | Citations (PDF) |
| 170 | Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk | 2.2 | 115 | Citations (PDF) |
| 171 | Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk | 2.2 | 263 | Citations (PDF) |
| 172 | Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer | 8.1 | 32 | Citations (PDF) |
| 173 | Identification of Inherited Genetic Variations Influencing Prognosis in Early-Onset Breast Cancer | 4.2 | 42 | Citations (PDF) |
| 174 | Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer | 11.0 | 155 | Citations (PDF) |
| 175 | Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31 | 11.0 | 108 | Citations (PDF) |
| 176 | 19p13.1 Is a Triple-Negative–Specific Breast Cancer Susceptibility Locus | 4.2 | 106 | Citations (PDF) |
| 177 | Pathology of Breast and Ovarian Cancers among
BRCA1
and
BRCA2
Mutation Carriers: Results from the Consortium of Investigators of Modifiers of
BRCA1
/
2
(CIMBA) | 0.6 | 627 | Citations (PDF) |
| 178 | Genome-wide association analysis identifies three new breast cancer susceptibility loci | 14.1 | 273 | Citations (PDF) |
| 179 | Screening of Finnish RAD51Cfounder mutations in prostate and colorectal cancer patients | 2.1 | 10 | Citations (PDF) |
| 180 | Effect of image compression and scaling on automated scoring of immunohistochemical stainings and segmentation of tumor epithelium | 1.8 | 24 | Citations (PDF) |
| 181 | A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11 | 2.1 | 174 | Citations (PDF) |
| 182 | Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers | 3.4 | 84 | Citations (PDF) |
| 183 | Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies | 3.4 | 631 | Citations (PDF) |
| 184 | A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer | 14.1 | 298 | Citations (PDF) |
| 185 | Breast tumors from CHEK2 1100delC- mutation carriers: genomic landscape and clinical implications | 3.4 | 62 | Citations (PDF) |
| 186 | Variants on the promoter region of PTEN affect breast cancer progression and patient survival | 3.4 | 47 | Citations (PDF) |
| 187 | Data Integration Workflow for Search of Disease Driving Genes and Genetic Variants | 1.5 | 4 | Citations (PDF) |
| 188 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers | 2.1 | 70 | Citations (PDF) |
| 189 | RAD51C is a susceptibility gene for ovarian cancer | 2.1 | 132 | Citations (PDF) |
| 190 | NQO1 expression correlates inversely with NFκB activation in human breast cancer | 1.8 | 26 | Citations (PDF) |
| 191 | Breast tumors from CHEK2 1100delC mutation carriers: genomic landscape and clinical implications | 3.4 | 3 | Citations (PDF) |
| 192 | MiR-34a Expression Has an Effect for Lower Risk of Metastasis and Associates with Expression Patterns Predicting Clinical Outcome in Breast Cancer | 1.5 | 75 | Citations (PDF) |
| 193 | Common variants at 19p13 are associated with susceptibility to ovarian cancer | 14.1 | 251 | Citations (PDF) |
| 194 | A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24 | 14.1 | 341 | Citations (PDF) |
| 195 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population | 14.1 | 320 | Citations (PDF) |
| 196 | Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for
BRCA1
and
BRCA2
Mutation Carriers: Implications for Risk Prediction | 4.2 | 176 | Citations (PDF) |
| 197 | Glycodelin expression associates with differential tumour phenotype and outcome in sporadic and familial non-BRCA1/2 breast cancer patients | 1.8 | 17 | Citations (PDF) |
| 198 | A combined analysis of genome-wide association studies in breast cancer | 1.8 | 93 | Citations (PDF) |
| 199 | Association of ESR1 gene tagging SNPs with breast cancer risk | 2.1 | 87 | Citations (PDF) |
| 200 | Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers | 2.1 | 100 | Citations (PDF) |
| 201 | The combined status of ATM and p53 link tumor development with therapeutic response | 2.9 | 282 | Citations (PDF) |
| 202 | High cyclin B1 expression is associated with poor survival in breast cancer | 4.2 | 128 | Citations (PDF) |
| 203 | Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients | 3.4 | 37 | Citations (PDF) |
| 204 | Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers | 4.5 | 267 | Citations (PDF) |
| 205 | NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer | 14.1 | 193 | Citations (PDF) |
| 206 | Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk | 2.1 | 31 | Citations (PDF) |
| 207 | Comprehensive analysis of NuMAvariation in breast cancer | 2.1 | 6 | Citations (PDF) |
| 208 | Aberrations of the MRE11–RAD50–NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer‐predisposing gene | 2.8 | 156 | Citations (PDF) |
| 209 | Basal cytokeratins in breast tumours among BRCA1, BRCA2and mutation-negative breast cancer families | 3.4 | 24 | Citations (PDF) |
| 210 | The importance of replication in gene-gene interaction studies: multifactor dimensionality reduction applied to a two-stage breast cancer case-control study | 2.2 | 24 | Citations (PDF) |
| 211 | Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics | 2.2 | 325 | Citations (PDF) |
| 212 | Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer | 1.8 | 61 | Citations (PDF) |
| 213 | RAD51 135G→C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies | 4.5 | 222 | Citations (PDF) |
| 214 | A common coding variant in CASP8 is associated with breast cancer risk | 14.1 | 604 | Citations (PDF) |
| 215 | Genome-wide association study identifies novel breast cancer susceptibility loci | 31.3 | 2,220 | Citations (PDF) |
| 216 | Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut‐off values? | 2.6 | 62 | Citations (PDF) |
| 217 | Mast cells and eosinophils in invasive breast carcinoma | 2.1 | 75 | Citations (PDF) |
| 218 | The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer | 5.2 | 104 | Citations (PDF) |
| 219 | Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer | 2.2 | 25 | Citations (PDF) |
| 220 | The CHEK2 gene and inherited breast cancer susceptibility | 5.2 | 197 | Citations (PDF) |
| 221 | BACH1 Ser919Pro variant and breast cancer risk | 2.1 | 29 | Citations (PDF) |
| 222 | ATM variants and cancer risk in breast cancer patients from Southern Finland | 2.1 | 23 | Citations (PDF) |
| 223 | Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides | 4.2 | 24 | Citations (PDF) |
| 224 | The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li–Fraumeni syndrome and related phenotypes | 2.1 | 95 | Citations (PDF) |
| 225 | Pancreatic Secretory Trypsin Inhibitor (SPINK1) Gene Mutations in Patients With Acute Pancreatitis | 0.9 | 42 | Citations (PDF) |
| 226 | Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients | 2.8 | 100 | Citations (PDF) |
| 227 | Mutations N34S and P55S of the SPINK1 gene in patients with chronic pancreatitis or pancreatic cancer and in healthy subjects: A report from Finland | 1.1 | 49 | Citations (PDF) |
| 228 | Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2and mutation-negative breast cancer families | 3.4 | 64 | Citations (PDF) |
| 229 | BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition | 2.1 | 42 | Citations (PDF) |
| 230 | Characterization of monoclonal antibodies against prostate specific antigen produced by genetic immunization | 1.0 | 13 | Citations (PDF) |
| 231 | CHEK2 variant I157T may be associated with increased breast cancer risk | 2.8 | 147 | Citations (PDF) |
| 232 | Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families | 3.4 | 89 | Citations (PDF) |
| 233 | Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies | 4.5 | 3,363 | Citations (PDF) |
| 234 | Hereditary Breast Cancer and Handling of Patients at Risk | 1.3 | 7 | Citations (PDF) |
| 235 | Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: A relative survival analysis from Finland | 2.8 | 55 | Citations (PDF) |
| 236 | Involvement ofBRCA1 andBRCA2 in breast cancer in a western Finnish sub-population | 2.5 | 8 | Citations (PDF) |
| 237 | Title is missing! | 1.2 | 25 | Citations (PDF) |
| 238 | Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites | 4.2 | 39 | Citations (PDF) |
| 239 | BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients | 2.1 | 50 | Citations (PDF) |
| 240 | Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families | 2.1 | 23 | Citations (PDF) |
| 241 | Exclusion of large deletions and other rearrangements in BRCA1 and BRCA2 in Finnish breast and ovarian cancer families | 1.6 | 42 | Citations (PDF) |
| 242 | BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families | 3.7 | 11 | Citations (PDF) |
| 243 | A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families | 4.2 | 86 | Citations (PDF) |
| 244 | Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland | 2.1 | 82 | Citations (PDF) |
| 245 | Population-Based Study of BRCA1 and BRCA2 Mutations in 1035 Unselected Finnish Breast Cancer Patients | 3.4 | 160 | Citations (PDF) |
| 246 | Familial breast cancer in southern Finland | 3.5 | 91 | Citations (PDF) |
| 247 | Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence | 4.2 | 107 | Citations (PDF) |
| 248 | Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes | 2.1 | 128 | Citations (PDF) |
| 249 | Breast cancer risk estimation in families with history of breast cancer | 4.2 | 3 | Citations (PDF) |
| 250 | Amplification offgfr4 gene in human breast and gynecological cancers | 2.8 | 157 | Citations (PDF) |
| 251 | The genes for CD37, CD53, and R2, all members of a novel gene family, are located on different chromosomes | 1.1 | 16 | Citations (PDF) |
| 252 | Bg/ll restriction fragment length polymorphism at the gene locus coding for the leukocyte surface antigen CD37 | 2.1 | 1 | Citations (PDF) |
| 253 | Localization of gene for human syndecan, an integral membrane proteoglycan and a matrix receptor, to chromosome 2 | 1.3 | 12 | Citations (PDF) |
| 254 | Title is missing! 0 | | 1 | Citations (PDF) |
